Claims for Patent: 12,403,086
✉ Email this page to a colleague
Summary for Patent: 12,403,086
| Title: | Solid drug tablets for implantable drug delivery devices |
| Abstract: | A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesthetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. |
| Inventor(s): | Karen Danielle Daniel, Burleigh M. Hutchins, III, Cheryl Larrivee-Elkins, Heejin Lee |
| Assignee: | Taris Biomedical LLC |
| Application Number: | US18/516,052 |
| Patent Claims: |
1. A method of manufacturing an assembly of tablets, comprising: providing a plurality of tablets formed from a drug composition comprising a combination of a drug and one or more excipients, wherein the tablets are in the form of mini-tablets, wherein each mini-tablet is cylindrical with flat end faces, the length of the mini-tablet exceeding its diameter so that the mini-tablet has an aspect ratio of greater than 1:1; arranging the plurality of tablets in a serial arrangement in which the flat end faces of adjacent tablets face one another; and loading the serial arrangement into a drug delivery device which is configured for deployment within the body of a patient. 2. The method of claim 1, wherein the providing the plurality of tablets comprises a process that includes granulating the drug and the one or more excipients to form the drug composition, and then tableting the drug composition. 3. The method of claim 2, wherein the granulating comprises slugging, roller compaction, or fluid bed granulation. 4. The method of claim 1, further comprising sterilizing the plurality of tablets after arranging the plurality of tablets in a serial arrangement. 5. An assembly of tablets, comprising: a plurality of tablets in the form of mini-tablets containing a drug, wherein each mini-tablet is cylindrical with flat end faces, the length of the mini-tablet exceeding its diameter so that the mini-tablet has an aspect ratio of greater than 1:1, and wherein the plurality of tablets are configured in a serial arrangement in which the flat end faces of adjacent tablets face one another, wherein the serial arrangement is disposed within a drug delivery device configured for deployment within the body of a patient. 6. The assembly of claim 5, wherein the plurality of tablets comprises between 10 and 100 of the tablets. 7. The assembly of claim 5, wherein the serial arrangement comprises interstices formed between adjacent ones of the tablets. 8. The assembly of claim 5, wherein each mini-tablet has a diameter from 1.0 mm to 3.2 mm and a length from 1.7 mm to 4.8 mm, such that the mini-tablet is sized and shaped for insertion through the urethra of a patient and into the bladder. 9. The assembly of claim 8, wherein each mini-tablet has a diameter from 1.5 mm to 3.1 mm and a length from 2.0 mm to 4.5 mm. 10. The assembly of claim 5, wherein each mini-tablet contains greater than 70% by weight the drug. 11. The assembly of claim 5, wherein each mini-tablet comprises the drug in an amount between 70 wt % and 99 wt % of the mini-tablet. 12. The assembly of claim 5, wherein the drug is an anesthetic agent, an antimicrobial agent, or a chemotherapeutic agent. 13. The assembly of claim 5, wherein the mini-tablets further comprise excipients comprising a binder and a lubricant. 14. The assembly of claim 5, wherein each mini-tablet has a friability of less than 2%. 15. The assembly of claim 5, wherein each mini-tablet is sterilized. 16. The assembly of claim 5, wherein each mini-tablet has an aspect ratio from about 3:2 to about 5:2. 17. An assembly of drug tablets, comprising: a plurality of drug of tablets containing a drug, the plurality being from 10 to 100 drug tablets, wherein each tablet is cylindrical with flat end faces, the length of the tablet exceeding its diameter so that the tablet has an aspect ratio from 3:2 to 5:2, wherein the plurality of drug tablets are configured in a serial arrangement in which the flat end faces of adjacent tablets face one another, and wherein each tablet has a friability of less than 2%, wherein the serial arrangement is disposed within a drug delivery device configured for deployment within the body of a patient. 18. The assembly of claim 17, wherein the serial arrangement comprises interstices formed between adjacent ones of the tablets and the assembly is sized and shaped for insertion through the urethra of the patient and into the bladder of the patient. 19. The assembly of claim 18, wherein each tablet has a diameter from 1.5 mm to 3.1 mm and a length from 2.0 mm to 4.5 mm and comprises the drug in an amount between 70 wt % and 99 wt % of the tablet. 20. The assembly of claim 19, wherein the drug is a chemotherapeutic agent and the tablets comprise excipients comprising a binder and a lubricant. 21. The method of claim 1, wherein the drug comprises gemcitabine. 22. The assembly of claim 5, wherein the drug comprises gemcitabine. 23. The assembly of claim 17, wherein the drug comprises gemcitabine. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
